Agency: Cordis | Branch: H2020 | Program: RIA | Phase: BIOTEC-1-2014 | Award Amount: 7.06M | Year: 2015
P4SB is about the utilization of the conceptual and material tools of contemporary Synthetic Biology to bring about the sustainable and environmentally friendly bioconversion of oil-based plastic waste into fully biodegradable counterparts by means of deeply engineered, whole-cell bacterial catalysts. These tools will be used to design tailor-made enzymes for the bio-depolymerization of PET (polyethylene terephthalate) and PU (polyurethane), but also for the custom design of a Pseudomonas putida Cell Factory capable of metabolizing the resulting monomers. Pseudomonas putida will undergo deep metabolic surgery to channel these diverse substrates efficiently into the production of polyhydroxyalkanoates (PHA) and derivatives. In addition, synthetic downstream processing modules based on the programmed non-lytic secretion of PHA will facilitate the release and recovery of the bioplastic from the bacterial biomass. These industry driven objectives will help to address the market need for novel routes to valorise the gigantic plastic waste streams in the European Union and beyond, with direct opportunities for SME partners of P4SB spanning the entire value chain from plastic waste via Synthetic Biology to biodegradable plastic. As a result we anticipate a completely biobased process reducing the environmental impact of plastic waste by establishing it as a novel bulk second generation carbon source for industrial biotechnology, while at the same time opening new opportunities for the European plastic recycling industry and helping to achieve the ambitious recycling targets set by the European Union for 2020.
News Article | February 15, 2017
Quadrant Engineering Plastic Products (Quadrant EPP) has announced a new series of Stable Machining Grade (SMG) materials, developed to improve the performance and productivity of parts made from polyolefin base materials. Quadrant EPP has utilized its R&D capabilities to create the new materials—each to be launched over the next 6 months. “Quadrant’s considerable technical experience helped to meet customer needs that simply hadn’t been addressed by anyone in the market. Each of these new materials stretches the boundaries that may have existed for machinable shapes manufactured from PP (polypropylene) and PE (polyethylene),” said Doug Mahler, Product Marketing Manager. Research was done at several facilities in Quadrant’s North American operations area, including Scranton, PA; Reading, PA; Delmont, PA; and Fort Wayne, IN. The new materials each have a special performance characteristic, such as dimensional stability, higher temperature resistance, or enhanced purity. Each formulation was developed based on market feedback—some of it segment specific—that helped researchers better understand the problems machine builders were having with existing, traditional olefin formulations. According to Bernie Willms, Commercial Director, North America, “Our research staff worked closely with our market development teammates around the world to define the performance for these products. Each of these [new products] will give our authorized distributors some unique solutions that people are asking for.” The products will be released in March and June of 2017. Each will hit the market with inventory already in-place, along with a suite of collateral and training materials. About Quadrant Engineering Plastic Products: For over 70 years, Quadrant Engineering Plastic Products (Quadrant EPP) has been proving there is simply no substitute for quality and innovation. Quadrant EPP is the global leader in research, development, and manufacture of machinable, high-performance engineering polymer materials. Quadrant EPP materials are specified for use in food processing and packaging, semiconductor manufacturing, aerospace, electronics, chemical processing, life sciences, power generation, and diverse industrial equipment. Quadrant EPP products range from UHMW polyethylene, nylon, and acetal to ultra-high performance polymers that resist temperatures to over 800°F (425°C). Quadrant EPP technology is backed by a global team of application development and technical service engineers, specializing in evaluating designs and fabrication techniques. Quadrant EPP materials expertise is available through a worldwide network of branch offices, technical support centers, and authorized dealers. Learn more about Quadrant EPP at http://www.quadrantplastics.com or connect with Quadrant EPP on Facebook, YouTube, and Twitter ("quadrantepp”). Registered trademarks of the Quadrant group of companies: Acetron®, CleanStat®, Duraspin®, Duratron®, Erta®, Ertalyte®, Ertalene®, Ertalon®, Extreme Materials®, Fluorosint®, Ketron®, MC®, Monocast®, Nylatron®, Nylasteel®, Polypenco®, Proteus®, Sanalite®, Semitron®, Techtron®, TIVAR® and Vibratuf®.
News Article | February 24, 2017
BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year 2016 before the market opens on Tuesday, March 7, 2017. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. The live webcast can be accessed in the “Investors & Media” section of our website, www.arqule.com, under “Events & Presentations." You may also listen to the call by dialing (877) 868-1831 within the U.S. or (914) 495-8595 outside the U.S. A replay will be available two hours after the completion of the call and can be accessed in the “Investors & Media” section of our website, www.arqule.com, under “Events and Presentations." ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s most advanced product, in phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase, for second-line treatment of MET-overexpressing hepatocellular carcinoma in partnership with Daiichi Sankyo in the West and Kyowa Hakko Kirin in Asia. ArQule’s proprietary pipeline includes: ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in phase 1 for multiple oncology indications as well as ultra-rare Proteus syndrome, in partnership with the National Institutes of Health (NIH); ARQ 751, a next generation AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. In addition, we have advanced ARQ 531, an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, through toxicology testing and plan to file an Investigational New Drug Application in early 2017. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds. You can follow us on Twitter and LinkedIn.
News Article | February 17, 2017
ArQule to host investor conference call on February 17, 2017 at 8:30 A.M. ET BURLINGTON, Mass. and TOKYO and MUNICH and PARSIPPANY, N.J., Feb. 17, 2017 /PRNewswire/ -- ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo today announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) did not meet its primary endpoint of improving overall survival. METIV-HCC is a biomarker-selected, double-blind, placebo-controlled, randomized phase 3 study evaluating tivantinib (2:1) versus best supportive care in patients with MET-overexpressing, inoperable HCC intolerant to or previously-treated with systemic therapy. A total of 340 patients with MET-overexpressing HCC analyzed by a validated immunohistochemical assay were randomized in the intent-to-treat population for efficacy analysis. The primary endpoint of the study is overall survival. Secondary endpoints include progression-free survival and safety. Full results from the trial will be presented at an upcoming scientific forum. "HCC is a disease with high unmet need, especially in the second-line setting, so these results are disappointing for the patients as well as the investigators and the companies," said Paolo Pucci, Chief Executive Officer of ArQule. "Despite the negative outcome of this study, we remain committed to applying rigorous science to unmet needs for patients with cancer," said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo. "We would like to take this opportunity to thank all of the investigators, and especially the patients, for their participation in this study." The ArQule investor conference call can be accessed in the "Investors and Media" section of ArQule's website, www.arqule.com, under "Events and Presentations." You may also listen to the call by dialing (877) 868-1831 within the U.S. or (914) 495-8595 outside the U.S. and using the passcode 74015633. A replay will be available two hours after the completion of the call and can be accessed in the "Investors and Media" section of our website, www.arqule.com, under "Events and Presentations." About Hepatocellular Carcinoma (HCC) Liver cancer is the sixth most common cancer globally with 782,000 new cases in 2012 and is the second most common cause of cancer-related death with 745,000 deaths in 2012.1 HCC accounts for about 90 percent of primary liver cancers.2 Cirrhosis, chronic hepatitis B and C and smoking are recognized worldwide as factors increasing the risk of HCC.2 About Tivantinib (ARQ 197) ArQule and Daiichi Sankyo have a licensing, co-development and co-commercialization agreement for tivantinib in the U.S., Europe, South America and the rest of the world, excluding Japan, China (including Hong Kong), South Korea and Taiwan. About ArQule ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule's lead product, in phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase, for second-line treatment of patients with MET-overexpressing hepatocellular carcinoma in partnership with Daiichi Sankyo in the West and Kyowa Hakko Kirin in Asia. ArQule's proprietary pipeline includes: ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in phase 1 for multiple oncology indications as well as ultra-rare Proteus syndrome, in partnership with the National Institutes of Health (NIH); ARQ 751, a next generation AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. In addition, we have advanced ARQ 531, an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, into toxicology testing and plan to file an Investigational New Drug Application in early 2017. ArQule's current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company's proprietary library of compounds. You can follow us on Twitter and LinkedIn. About Daiichi Sankyo Cancer Enterprise The vision of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our Antibody Drug Conjugate (ADC) and Acute Myeloid Leukemia (AML) franchises, our cancer pipeline includes more than 20 small molecules, monoclonal antibodies and ADCs stemming from our powerful research engines: our two laboratories for biologic/immuno-oncology and small molecules in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. Compounds in development include: quizartinib, an oral FLT3 inhibitor, for FLT3-ITD+ AML; DS-8201, a HER2-targeting ADC, for HER2-expressing breast or gastric cancer or other HER2-expressing solid tumors; pexidartinib, an oral CSF-1R inhibitor, for tenosynovial giant cell tumor (TGCT), which is also being explored in a range of solid tumors in combination with the anti-PD1 immunotherapy, pembrolizumab; and tivantinib, an oral MET inhibitor, for second-line treatment of patients with MET-overexpressing hepatocellular carcinoma in partnership with ArQule, Inc. About Daiichi Sankyo Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit: www.dsi.com. This press release contains forward-looking statements regarding the Company's clinical trials with tivantinib (ARQ 197). These statements are based on the Company's current beliefs and expectations, and are subject to risks and uncertainties that could cause actual results to differ materially. Positive information about pre-clinical and early stage clinical trial results does not ensure that later stage or larger scale clinical trials will be successful. For example, tivantinib may not demonstrate promising therapeutic effect or appropriate safety profiles in current or later stage or larger scale clinical trials as a result of known or as yet unanticipated side effects. The results achieved in later stage trials may not be sufficient to meet applicable regulatory standards or to justify further development. Problems or delays may arise prior to the initiation of planned clinical trials, during clinical trials or in the course of developing, testing or manufacturing that could lead the Company or its partners and collaborators to fail to initiate or to discontinue development. Even if later stage clinical trials are successful, unexpected concerns may arise from subsequent analysis of data or from additional data. Obstacles may arise or issues may be identified in connection with review of clinical data with regulatory authorities. Regulatory authorities may disagree with the Company's view of the data or require additional data or information or additional studies. In addition, the planned timing of initiation and completion of clinical trials for tivantinib is subject to the ability of the Company as well as Daiichi Sankyo, Inc., our development partner for tivantinib, and Kyowa Hakko Kirin, a licensee of tivantinib, to enroll patients, enter into agreements with clinical trial sites and investigators, and overcome technical hurdles and other issues related to the conduct of the trials for which each of them is responsible. There is a risk that these issues may not be successfully resolved. In addition, we and our partners are utilizing companion diagnostic tests to identify MET-overexpressing patients in the METIV-HCC, JET-HCC and other trials. We may encounter difficulties in developing and obtaining approval for companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators or us to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates. Drug development involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. Positive pre-clinical data may not be supported in later stages of development. Furthermore, ArQule may not have the financial or human resources to successfully pursue drug discovery in the future. Moreover, with respect to partnered programs, even if certain compounds show initial promise, Daiichi Sankyo or Kyowa Hakko Kirin may decide not to license or continue to develop them, as the case may be. In addition, Daiichi Sankyo and Kyowa Hakko Kirin have certain rights to unilaterally terminate their agreements with ArQule. If either company were to do so, the Company might not be able to complete development and commercialization of the applicable licensed products on its own. For more detailed information on the risks and uncertainties associated with the Company's drug development and other activities, see the Company's periodic reports filed with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update any forward-looking statements.
Proteus, French Institute of Petroleum and French National Center for Scientific Research | Date: 2013-09-04
The invention relates to a polypeptide which has enhanced beta-glucosidase activity at a temperature of between about 30 C. and about 35 C.
News Article | February 23, 2017
Houston, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Shell Midstream Partners, L.P. (NYSE: SHLX), a growth-oriented mainstream midstream master limited partnership formed by Royal Dutch Shell plc (RDS), reported net income attributable to the partnership of $69.5 million for the fourth quarter of 2016, which equated to $0.34 per common limited partner unit. Shell Midstream Partners also generated adjusted earnings before interest, income taxes, depreciation and amortization attributable to the partnership of $84.3 million and cash available for distribution of $82.7 million. "Executing our strategy and continuing to grow our business has provided for strong fourth quarter results as well as for a strong 2016. The recent third-party acquisition of three offshore pipelines is a great example of an opportunity that enhanced our portfolio and directly supported our strategy," said John Hollowell, CEO of Shell Midstream Partners. "As we look to 2017, we will continue to diversify our portfolio and further highlight the depth of growth opportunities across the Royal Dutch Shell portfolio in North America." During the fourth quarter, Shell Midstream Partners completed the acquisition of a 10.0% interest in Proteus Oil Pipeline Company, LLC ("Proteus"), a 10.0% interest in Endymion Oil Pipeline Company, LLC ("Endymion"), and a 1.0% interest in Cleopatra Gas Gathering Company, LLC ("Cleopatra") from BP for $42.0 million. This acquisition directly supports the partnership's offshore corridor pipeline strategy. Proteus and Endymion will connect the Mattox pipeline to onshore markets, creating a new corridor line, which will transport all of Appomattox's volumes once it comes online toward the end of the decade. The Board of Directors of the general partner previously declared a cash distribution of $0.2770 per limited partnership unit for the fourth quarter of 2016. This distribution represented an increase of 5.0% over the third quarter 2016 distribution and 26.0% increase over the fourth quarter 2015 distribution. This represents the eighth consecutive quarter of distribution growth and 2016 annual growth above the previously targeted rate of 25.0%. The distribution coverage ratio was 1.4x for the fourth quarter. • Net income attributable to the partnership was $69.5 million, compared to $56.3 million for the prior quarter, primarily driven by the acquisition of a 49% interest in Odyssey Pipeline, L.L.C. and a 20% interest in Mars Oil Pipeline Company. • Cash available for distribution was $82.7 million, compared to $61.1 million for the prior quarter, representing a 35.4% increase quarter on quarter. • Total cash distributions declared were $58.6 million resulting in a 1.4x coverage ratio. • Adjusted EBITDA attributable to the partnership was $84.3 million compared to $68.0 million for the prior quarter, representing an increase of 24.0% above the third quarter. • As of December 31, 2016, the partnership had $121.9 million of consolidated cash and cash equivalents on hand and $686.0 million of total debt outstanding. • In December, the partnership acquired a 10.0% interest in Proteus Oil Pipeline Company, LLC, a 10.0% interest in Endymion Oil Pipeline Company, LLC, and a 1.0% interest in Cleopatra Gas Gathering Company, LLC for $42.0 million. The acquisition was funded using borrowings under the revolving credit facilities. • Shell Midstream Partners is in the process of entering into a new 5-year $600 million fixed rate facility. On a pro forma basis, as of December 31, 2016, total credit facilities of the partnership including the new facility and following the expiration of the 364-day facility, was $1.39 billion. On a pro forma basis, total debt capacity remaining under the facilities plus cash on hand was $826 million. Cash available for distribution and Adjusted EBITDA are non-GAAP supplemental financial measures. See reconciliation tables later in this press release. Crude Systems and Related Storage ◦ Zydeco - The partnership saw steady demand to move onshore and offshore crude to key markets in Louisiana. Mainline volumes were 628 kbpd in the current quarter, compared to 545 kbpd in the prior quarter. ◦ Lockport - Storage volumes remained steady as the terminal is fully utilized. ◦ Auger - Volumes were 105 kbpd, substantially flat from the prior quarter of 103 kbpd. ◦ Mars - Volumes were 396 kbpd compared to 461 kbpd in the prior quarter primarily due to deliveries out of the caverns as storage positions unwound with increasing crude prices during the third quarter. The average run rate of underlying volumes on the system is about 400 kbpd. ◦ Poseidon - Volumes were 273 kbpd, slightly higher than the prior quarter of 264 kbpd due to continued demand on the system for deliveries into Houma. ◦ Odyssey - Volumes were 107 kbpd. The acquisition of a 49.0% interest in Odyssey closed October 3, 2016. Refined Products Systems and Related Storage ◦ Colonial - Dividends were in line with the third quarter. Based on current forecasts, Colonial does not expect any further material repair expenses related to the events that occurred in late 2016. ◦ Explorer - The acquisition of 2.62% of Explorer closed August 9, 2016. Volumes were in line with expectations. ◦ Bengal - Volumes were 540 kbpd, in line with the previous prior quarter of 537 kbpd. The tank repairs are expected to be completed and returned to service by Q3 2017. Normal operations will continue while tank repairs are ongoing. Shell Midstream Partners, headquartered in Houston, Texas, is a fee-based, growth-oriented midstream master limited partnership formed by Royal Dutch Shell to own, operate, develop and acquire pipelines and other midstream assets. Shell Midstream Partners' assets consist of pipelines, crude tank storage and terminal systems that serve as key infrastructure to transport and store onshore and offshore crude oil production to Gulf Coast and Midwest refining markets and to deliver refined products from Gulf Coast markets to major demand centers. For more information on Shell Midstream Partners and the assets owned by the partnership, please visit www.shellmidstreampartners.com. At 10 a.m. CST today, Shell Midstream Partners will hold a webcast to discuss the reported results and provide an update on partnership operations. Interested parties may listen to the conference call on Shell Midstream Partners’ website at by clicking on the “2016 Fourth-Quarter Financial Results Webcast” link, found under the "Events and Conferences" section. A replay of the conference call will be available following the live webcast. (1) Deferred revenue for the three months ended December 31, 2016 and September 30, 3016, including the impact of overshipments and expiring credits, was $2.8 million and $1.9 million, respectively. See "Non-GAAP Financial Measures" later in this press release. See "Non-GAAP Financial Measures" later in this press release. (1) Non-GAAP measures. See reconciliation tables earlier in this press release. (2) Coverage ratio is equal to Cash available for distribution attributable to the partnership divided by Total distribution declared. (1) Pipeline throughput is defined as the volume of delivered barrels. (2) Odyssey was acquired by the partnership on October 3, 2016. Pipeline throughput prior to this date relates to periods when the 49% interest in Odyssey was owned by Shell Oil Products US. (3) Terminaling throughput is defined as the volume of delivered barrels and storage is defined as the volume of stored barrels. (4) Based on reported revenues from transportation and allowance oil divided by delivered barrels over the same time period. Actual tariffs charged are based on shipping points along the pipeline system, volume and length of contract. (5) Based on reported revenues from transportation and storage divided by delivered and stored barrels over the same time period. Actual rates are based on contract volume and length. This press release includes various “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements expressing management’s expectations, beliefs, estimates, forecasts, projections and assumptions. You can identify our forward-looking statements by words such as “anticipate”, “believe”, “estimate”, “expect”, “forecast”, “goals”, “objectives”, “outlook”, “intend”, “plan”, “predict”, “project”, “risks”, “schedule”, “seek”, “target”, “could”, “may”, “should” or “would” or other similar expressions that convey the uncertainty of future events or outcomes. In accordance with “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, these statements are accompanied by cautionary language identifying important factors, though not necessarily all such factors, which could cause future outcomes to differ materially from those set forth in forward-looking statements. In particular, expressed or implied statements concerning future growth, future actions, closing and funding of acquisitions, future drop downs, volumes, capital requirements, conditions or events, future impact of prior acquisitions, future operating results or the ability to generate sales, income or cash flow or the amount of distributions are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve risks, uncertainties and assumptions. Future actions, conditions or events and future results of operations may differ materially from those expressed in these forward-looking statements. Forward-looking statements speak only as of the date of this press release, February 23, 2017 and we disclaim any obligation to update such statements for any reason, except as required by law. All forward-looking statements contained in this document are expressly qualified in their entirety by the cautionary statements contained or referred to in this paragraph. Many of the factors that will determine these results are beyond our ability to control or predict. These factors include the risk factors described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, as updated by the information in our other filings with the SEC. If any of those risks occur, it could cause our actual results to differ materially from those contained in any forward-looking statement. Because of these risks and uncertainties, you should not place undue reliance on any forward-looking statement. This press release includes the terms Adjusted EBITDA and cash available for distribution. We believe that the presentation of Adjusted EBITDA and cash available for distribution provides useful information to investors in assessing our financial condition and results of operations. Adjusted EBITDA and cash available for distribution are non-GAAP supplemental financial measures that management and external users of our condensed consolidated financial statements, such as industry analysts, investors, lenders and rating agencies, may use to assess: • our operating performance as compared to other publicly traded partnerships in the midstream energy industry, without regard to historical cost basis or, in the case of Adjusted EBITDA, financing methods; • the ability of our business to generate sufficient cash to support our decision to make distributions to our unitholders; • our ability to incur and service debt and fund capital expenditures; and • the viability of acquisitions and other capital expenditure projects and the returns on investment of various investment opportunities. The GAAP measures most directly comparable to Adjusted EBITDA and cash available for distribution are net income and net cash provided by operating activities. These non-GAAP measures should not be considered as alternatives to GAAP net income or net cash provided by operating activities. Adjusted EBITDA and cash available for distribution have important limitations as analytical tools because they exclude some but not all items that affect net income and net cash provided by operating activities. They should not be considered in isolation or as substitutes for analysis of our results as reported under GAAP. Additionally, because Adjusted EBITDA and cash available for distribution may be defined differently by other companies in our industry, our definition of Adjusted EBITDA and cash available for distribution may not be comparable to similarly titled measures of other companies, thereby diminishing their utility. References in this press release to Adjusted EBITDA refer to net income before income taxes, net interest expense, gain or loss from disposition of fixed assets, allowance oil reduction to net realizable value, and depreciation, amortization and accretion, cash distributed to Shell Midstream Partners, L.P. from equity investments for the applicable period, income from equity investments. We define Adjusted EBITDA attributable to Shell Midstream Partners as Adjusted EBITDA Adjusted EBITDA attributable to noncontrolling interests. References to cash available for distribution refer to Adjusted EBITDA attributable to Shell Midstream Partners, maintenance capital expenditures attributable to Shell Midstream Partners, net interest paid, cash reserves and income taxes paid, net adjustments from volume deficiency payments attributable to Shell Midstream Partners and certain one-time payments not reflected in net income. Cash available for distribution will not reflect changes in working capital balances. The information in this Report reflects the unaudited consolidated financial position and results of Shell Midstream Partners, L.P.
News Article | February 20, 2017
LONDON--(BUSINESS WIRE)--The General Data Protection Regulation (GDPR) (Regulation (EU) 2016/679) is a Regulation by which the European Parliament, the Council and the European Commission intend to strengthen and unify data protection for individuals within the European Union (EU). It also addresses export of personal data outside the EU. The Regulation will apply to most organisations, worldwide, that hold personal data on any EU citizen. GDPR comes into force on the 25th May 2018. GDPR is possibly the biggest legislative change of our time and will have huge implications for businesses that deal with personal data. The consequences of non-compliance are massive. Not only will a business be dealing with the direct financial cost of a breach in itself, severe fines of up to €20m or 4% of turnover, will be imposed. Add to that the irreparable loss of reputation and undoubted loss of clients, and the commercial enormity of GDPR starts to emerge. Businesses need to act now to ensure they are GDPR ready before the deadline. Risk management is at the heart of GDPR and therefore systems that can’t support GDPR will fast become obsolete or expose their users to the risk of substantial fines. Proteus-Cyber’s products are ideally placed to help get organisations ready for GDPR. Proteus®GDPReady™ fully supports the GDPR process, providing the DPO with a ready-made suite of tools to model business processes, define what sensitive data exists and where it is, and perform multi-phase Data Privacy Impact Assessments. For each site in your organisation our simple to use GDPR software toolkit allows you to: Proteus®GDPReady™ is available now. For more detailed information on how Proteus®GDPReady™ helps ensure your business is GDPR compliant please visit www.proteuscyber.com.
News Article | February 27, 2017
New Orleans is a city that knows how to eat, drink and be merry, and the best display of the city's bacchanalian expertise is Mardi Gras. True to form for a city that allows bars to stay open around the clock, the New Orleans Mardi Gras festival officially lasts for more than seven weeks. But the party really picks up this weekend and culminates on Feb. 28, or Fat Tuesday, which is the final day before Lent begins on Wednesday, March 1. Below is a list of parades scheduled for the final, and most exciting, days of the festival. NOMTOC (New Orleans's Most Talked About Club) Parade Route: Krewe of NOMTOC's parade starts on Fiesta Street and Holiday Drive in Algiers. The parade will then head northwest on General Meyer Avenue before heading west on Newton Street. Route: The Krewe of Isis have scheduled their parade to begin at Carondelet Street and Napoleon Avenue in Milan. The parade is then scheduled to head south to St. Charles Avenue, and follow it to Canal Street. Route: The Krewe of Tucks has set a parade route that starts in Touro at Magazine Street and Napoleon Avenue, and is scheduled to head north to St. Charles Avenue, before heading northeast to Canal Street. Route: The Krewe of Endymion has been named one of three "super krewes" for the stunning visual displays it has produced over the years. The Krewe of Endymion has set the starting point for their parade at City Park Avenue. The parade is scheduled to then head south along Orleans Avenue and turning to the southwest down South Carrollton Avenue before heading south down Canal Street. Route: The Krewe of Isis has planned its parade to begin on Trenton Avenue in Metaire near the Clearview Mall. The parade route then heads north to Veterans Memorial Boulevard, where it heads east to Martin Behrman Avenue. Route: The Krewe of Okeanos has planned its parade to begin at Jefferson Avenue and head east down Magazine Street before moving north up Napoleon Avenue to St. Charles Avenue. The parade is then scheduled to head northwest to Canal Street. Route: The Krewe of Mid-City has scheduled its parade to begin at Jefferson Avenue and Magazine Street, move North up Napoleon Avenue, then turn east along St. Charles before ending at Canal Street. Route: The Krewe of Thoth has planned its parade to start at State Street and Tchoupitoulas Street and head west, before turning north on Henry Clay Avenue, and then turning right on Magazine Street. The parade is scheduled to then head east to Napoleon Avenue before then turning east on St. Charles Avenue and traveling northeast to Canal Street. Route: Corps de Napoleon has planned its parade to start on Trenton Street in front of the Clearview Mall, turn north up Houma Boulevard to Veterans Memorial Boulevard. The parade is then scheduled to head east down Veterans Memorial Boulevard, with two detours up and down Severn Avenue and Bonnabel Boulevard, before ending at Martin Behrmann Avenue. Route: The Krewe of Bacchus, another "super krewe," has planned its parade to start at Tchoupitoulas Street and move north up Napoleon Avenue, before taking the familiar route along northeast along St. Charles Avenue toward Canal Street. New Orleans kicks off its famous Mardi Gras festival on Fat Tuesday, which this year falls on Feb. 28. Route: The Krewe of Proteus has planned its parade to start at Perrier Street and move north up Napoleon Avenue, before traveling down St. Charles Avenue toward Canal Street. Route: The Krewe of Orpheus, the third "super krewe," has planned its parade for Mandeville, which is across Lake Pontchartrain from New Orleans. The parade is set to start on Emerald Road west of St. Joseph Drive, turn south on West Causeway Approach, hop onto a parallel service road, and then move east down Monroe Street before traveling east down East Causeway Approach and ending at Galvez Street. Route: The Krewe of Zulu's parade is set to start at South Claiborne Avenue, travel south down Jackson Avenue to St. Charles Avenue, head northeast to Canal Street, turn north along Canal to Basin Street, then follow Basin Street, which becomes Orleans Avenue, to North Broad Street. Route: The Rex Organization has planned its parade to start to travel south down Napoleon Avenue between South Claiborne Avenue and St. Charles Avenue. The parade is then scheduled to travel northeast along St. Charles Street to Canal Street. Route: The Elks Orleans parade is scheduled to follow the same route as the Rex parade, will turn northwest at Canal Street, before turning southeast down South Robertson Street and ending at Tulane Avenue. Route: The Crescent City parade is scheduled to begin after the Elks Orleans parade and follow the same route. Route: The Krewe of Argus has planned its parade to start on Trenton Street in front of the Clearview Mall, turn north up Houma Boulevard to Veterans Memorial Boulevard. The parade is then scheduled to head east down Veterans Memorial Boulevard, with two detours up and down Severn Avenue and Bonnabel Boulevard, before ending at Martin Behrmann Avenue. Route: The Krewe of Elks Jefferson parade has planned its parade to start on Trenton Street in front of the Clearview Mall, turn north up Houma Boulevard to Veterans Memorial Boulevard. The parade is then scheduled to head east down Veterans Memorial Boulevard, with two detours up and down Severn Avenue and Bonnabel Boulevard, before ending at Martin Behrmann Avenue. Route: The Krewe of Elks Jefferson parade has planned its parade to start on Trenton Street in front of the Clearview Mall, turn north up Houma Boulevard to Veterans Memorial Boulevard. The parade is then scheduled to head east down Veterans Memorial Boulevard, with two detours up and down Severn Avenue and Bonnabel Boulevard, before ending at Martin Behrmann Avenue.
Proteus | Date: 2011-01-21
The invention provides for methods of generating modified polynucleotide libraries by inserting and/or deleting at least three nucleotide residues in polynucleotide sequences. Theses methods may be used with other methods of gene modification such as gene shuffling. The invention further provides methods of directed molecular evolution using the modified polynucleotide libraries produced by these methods.
News Article | February 20, 2017
LONDRES--(BUSINESS WIRE)--Proteus-Cyber Ltd, especialistas en software de gestión de riesgo integrado, han lanzado Proteus®GDPReady™. La empresa considera que se trata del primer kit de herramientas de software RGPD del mercado que es totalmente compatible con el proceso GDPR y ayuda a los responsables de la protección de datos (RPD) a que sus organizaciones cumplan con RGPD. El Reglamento general sobre protección de datos (RGPD) (Regulation (EU) 2016/679) es una norma por la que el Parlamento